Apimeds Pharmaceuticals appoints Erick J. Frim as CFO, replacing Mark Corrao

Apimeds Pharmaceuticals US, Inc.

Erick J. Frim, 67, appointed CFO effective May 30, 2025, succeeding Mark Corrao.
Mr. Frim has over 40 years of financial management experience, most recently as interim CFO of Helio Corporation.
Compensation: $2,500 per month for first 8 hours, $250 per hour thereafter under a one-year consulting agreement.
No familial relationships or reportable related-party transactions with the Company.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mark Corrao

Chief Financial Officer

APUS · Apimeds Pharmaceuticals US, Inc.

Effective: 2025-05-30
Successor: Erick J. Frim
Filed: Jun 05, 2025 23:59 UTC

On May 30, 2025, the Board of Directors of Apimeds Pharmaceuticals US, Inc. (the “Company”) appointed Erick J. Frim as Chief Financial Officer of the Company, replacing Mark Corrao.

Appointed

Erick J. Frim

Chief Financial Officer

APUS · Apimeds Pharmaceuticals US, Inc.

Effective: 2025-05-30
Filed: Jun 05, 2025 23:59 UTC

On May 30, 2025, the Board of Directors of Apimeds Pharmaceuticals US, Inc. (the “Company”) appointed Erick J. Frim as Chief Financial Officer of the Company, replacing Mark Corrao.

Source: SEC EDGAR

accession 0001213900-25-051567

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.